Is Kiniksa Pharmaceuticals International (KNSA) Undervalued As Earnings Per Share Keeps Improving?
Why Kiniksa Pharmaceuticals International Stock Just Drew Fresh Attention
Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) just posted third quarter results that showed higher basic and diluted earnings per share from continuing operations compared with the same period a year earlier.
The earnings update landed alongside a sharp move in Kiniksa Pharmaceuticals International's share price, with a 1 day share price return of 6.25% on the latest close at US$93.86 and a 30 day share price return of 17.65%, adding to year to date momentum of 123.45%.
Scan beyond Kiniksa Pharmaceuticals International’s earnings jump and price move to see how it stacks up against other hand picked healthcare names in 35 healthcare AI stocks.
After a very strong share price run and a clear step up in earnings, Kiniksa Pharmaceuticals International now poses a sharper question: Does the current valuation still leave enough upside to justify fresh risk?
Most Popular Narrative: 9% Undervalued
Kiniksa Pharmaceuticals International's fair value from the analyst consensus Narrative on Simply Wall St sits at about $103.63, versus a last close of $93.86, which frames the latest earnings jump against a still modest implied discount.
The company's consistently high payer coverage/approval rates (>90%), strong therapy compliance, and robust commercial execution (e.g., AI-driven marketing and digital outreach) position Kiniksa to realize scale efficiencies and improved net margins as sales grow, supporting operational leverage and expanding profitability.
See why 24 investors see Kiniksa Pharmaceuticals International as 9% undervalued.
Result: Fair Value of $103.63 (UNDERVALUED)
Still, the Kiniksa Pharmaceuticals International story leans heavily on ARCALYST, so slower uptake or tougher pricing pressure could quickly challenge those fair value assumptions.
Find out about the key risks to this Kiniksa Pharmaceuticals International narrative.
Another View on Kiniksa Pharmaceuticals International’s Valuation
The analyst fair value points to Kiniksa Pharmaceuticals International trading at about a 9% discount, yet the current P/E of 67.3x tells a different story. That multiple is far above both the US Biotechs sector at 15.4x and the peer average at 39.8x. It is also almost double the 35x fair ratio level the regression model suggests the market could move toward over time. If sentiment cools, how much room is there for the valuation to compress even if the business keeps executing?
See what the numbers say about this price in our valuation breakdown, then compare it with your own expectations for margins and growth over the next few years. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Kiniksa Pharmaceuticals International is split, with clear positives and meaningful concerns pulling in opposite directions. Move quickly, review the underlying data and pressure test the story against your own risk tolerance and time horizon, then weigh both sides through 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Kiniksa Pharmaceuticals International?
If Kiniksa Pharmaceuticals International sharpened your focus on quality, do not stop here. Broaden your opportunity set with other ideas filtered by clear, consistent rules.
- Target steadier potential outcomes by reviewing companies screened for resilience in a 31 resilient stocks with low risk scores list that puts downside control front and center.
- Hunt for strong businesses priced below what their fundamentals suggest they could justify through a focused set of 39 high quality undervalued stocks.
- Zero in on underfollowed opportunities with solid numbers by scanning 19 high quality undiscovered gems before others pay attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com